Replies to post #123628 on Biotech Values

[DewDiligence]

In other words, Neugranin does not infringe on AMGN’s Neulasta patents, but it does infringe on AMGN’s Neupogen patents; thus, it makes sense that the AMGN-Teva settlement calls for Neugranin to be launched when the Neupogen patents expire in Nov 2013.

Do you agree with the inference in the bottom paragraph of #msg-65308970, i.e. that the Neulasta knockoff from Ratiopharm will not be brought to market in the US?

[stockbettor]

Apologies, I should have made my response clearer. I was referring to Amgen's Neulasta patent (5,824,784, link below), which pegylates G-CSF to make it long acting. This patent runs until October 2015. I conducted a quick search for a patent or P/A covereing ratiopharm's pegged version but could not find one.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,824,784.PN.&OS=PN/5,824,784&RS=PN/5,824,784